PH12019500431A1 - Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection - Google Patents

Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection

Info

Publication number
PH12019500431A1
PH12019500431A1 PH12019500431A PH12019500431A PH12019500431A1 PH 12019500431 A1 PH12019500431 A1 PH 12019500431A1 PH 12019500431 A PH12019500431 A PH 12019500431A PH 12019500431 A PH12019500431 A PH 12019500431A PH 12019500431 A1 PH12019500431 A1 PH 12019500431A1
Authority
PH
Philippines
Prior art keywords
tetanus
monoclonal antibodies
infection
immunotherapy
accidents
Prior art date
Application number
PH12019500431A
Inventor
Ana Maria Moro
Filho Jorge Elias Kalil
Eduardo Aliprandini
Original Assignee
Funda€Ao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Funda€Ao Butantan filed Critical Funda€Ao Butantan
Publication of PH12019500431A1 publication Critical patent/PH12019500431A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to human anti-tetanus monoclonal antibodies against C. tetani infection, obtained by genetic engineering techniques using the information about the gene sequence obtained from B lymphocytes in the peripheral blood of persons vaccinated with tetanus toxoid. The genetic information is inserted into vectors used for transfecting mammal cells, with the aim of generating cell lines producing anti-tetanus monoclonal antibodies. Another aspect of the present invention relates to immunological compositions containing said monoclonal antibody, and to the uses thereof for the treatment and/or immunotherapy of tetanus infection.
PH12019500431A 2016-07-29 2019-02-27 Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection PH12019500431A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016017782-0A BR102016017782A2 (en) 2016-07-29 2016-07-29 NUTRIENTING ANTITETANIC HUMAN MONOCLONAL ANTIBODIES FOR C.TETANI INFECTION, METHOD FOR OBTAINING MONOCLONAL ANTIBODIES AND THEIR USE IN IMMUNOTHERAPY FOR TETANIC BACILE INFECTION
PCT/BR2017/050215 WO2018018123A2 (en) 2016-07-29 2017-07-28 Human anti-tetanus monoclonal antibodies neutralising infection by c. tetani, method for obtaining said monoclonal antibodies and use thereof in immunotherapy in the case of accidents with possible infection by tetanus bacillus

Publications (1)

Publication Number Publication Date
PH12019500431A1 true PH12019500431A1 (en) 2019-10-28

Family

ID=59955306

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500431A PH12019500431A1 (en) 2016-07-29 2019-02-27 Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection

Country Status (4)

Country Link
AR (3) AR109221A1 (en)
BR (1) BR102016017782A2 (en)
PH (1) PH12019500431A1 (en)
WO (1) WO2018018123A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845609B (en) * 2019-11-26 2021-06-15 武汉生物制品研究所有限责任公司 Detection antibody pair aiming at tetanus toxoid and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2627076B2 (en) * 1988-08-19 1997-07-02 森永製菓株式会社 Anti-tetanus toxin human monoclonal antibody, neutralizing agent for tetanus toxin using the same, and hybridoma producing human monoclonal antibody
DE69225791T2 (en) * 1992-03-23 1998-10-22 Schweiz Serum & Impfinst Monoclonal antibodies to tetanus toxin and pharmaceutical compositions containing them
JPH1014570A (en) 1996-07-05 1998-01-20 Morihiro Matsuda Antibody dna
CN102453091B (en) 2010-10-20 2013-09-25 上海生物制品研究所有限责任公司 Tetanus toxoid monoclonal antibody and preparation method and application thereof
CN105153305B (en) 2015-06-26 2019-03-01 安泰吉（北京）生物技术有限公司 A kind of full humanized anti-spasmotoxin monoclone antibody and its derivative preparation method and application

Also Published As

Publication number Publication date
WO2018018123A2 (en) 2018-02-01
AR125232A2 (en) 2023-06-28
AR125231A2 (en) 2023-06-28
WO2018018123A3 (en) 2018-03-22
AR109221A1 (en) 2018-11-07
BR102016017782A2 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
Greyer et al. T cell help amplifies innate signals in CD8+ DCs for optimal CD8+ T cell priming
AU2019283892A1 (en) Anti-human papillomavirus 16 E7 T cell receptors
EA202190295A1 (en) T-cells with a chimeric antigenic receptor derived from pluripotent stem cells obtained by means of immunoengineering
MX2021000193A (en) Personalized cancer vaccine epitope selection.
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
MY173004A (en) Mycobacterial antigen vaccine
MX2018010586A (en) Sting activating nanovaccine for immunotherapy.
MX2020001198A (en) Binding agents binding to pd-l1 and cd137 and use thereof.
MY189819A (en) Genetically modified cells and uses thereof
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
GB2540694A (en) CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
MX2021004140A (en) Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof.
MY200886A (en) Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
BR112014011229A2 (en) compositions and methods for the treatment of cytomegalovirus
MX2011009437A (en) Antigen presenting cell targeted cancer vaccines.
WO2018185709A9 (en) Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
EA201500054A1 (en) ATTENUATED VACCINES AGAINST STREPTOCOCCUS SUIS AND METHODS OF THEIR RECEIVING AND APPLICATION
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2016073595A8 (en) T cells and dendritic cells for polyomavirus therapy
PH12017500722A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX349657B (en) Protein matrix vaccine compositions including polycations.
MX2016014868A (en) Methods for freeze-drying and rehydrating biologics.
Martelet et al. Porcine dendritic cells as an in vitro model to assess the immunological behaviour of Streptococcus suis subunit vaccine formulations and the polarizing effect of adjuvants
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
PH12019500431A1 (en) Neutralizing anti-tetanus human monoclonal antibodies for c. tetani infection, method of obtaining said monoclonal antibodies and their use in immunotherapy for accidents susceptible to tetanus bacillus infection